Nkarta (NASDAQ:NKTX) Given New $14.00 Price Target at Mizuho

Nkarta (NASDAQ:NKTX) had its target price decreased by investment analysts at Mizuho from $16.00 to $14.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage presently has an “outperform” rating on the stock.

NKTX has been the subject of a number of other reports. Stifel Nicolaus reduced their price objective on shares of Nkarta from $15.00 to $14.00 and set a “buy” rating for the company in a research report on Thursday, March 27th. Needham & Company LLC reduced their target price on Nkarta from $11.00 to $10.00 and set a “buy” rating for the company in a report on Thursday, May 15th. William Blair reiterated a “market perform” rating on shares of Nkarta in a report on Thursday, May 15th. Finally, HC Wainwright reissued a “buy” rating and issued a $18.00 price objective on shares of Nkarta in a research report on Thursday, March 27th. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $14.33.

Nkarta Stock Performance

NASDAQ:NKTX traded up $0.16 during mid-day trading on Tuesday, reaching $2.03. 158,902 shares of the company’s stock were exchanged, compared to its average volume of 1,125,587. The firm has a market capitalization of $144.04 million, a PE ratio of -1.08 and a beta of 0.72. Nkarta has a one year low of $1.31 and a one year high of $8.23. The business’s fifty day simple moving average is $1.82 and its two-hundred day simple moving average is $2.07.

Nkarta (NASDAQ:NKTX) last posted its earnings results on Wednesday, May 14th. The company reported ($0.43) EPS for the quarter, beating the consensus estimate of ($0.44) by $0.01. As a group, equities research analysts forecast that Nkarta will post -1.7 EPS for the current year.

Institutional Investors Weigh In On Nkarta

A number of institutional investors and hedge funds have recently modified their holdings of the company. Invesco Ltd. acquired a new stake in Nkarta during the fourth quarter worth about $30,000. Sequoia Financial Advisors LLC acquired a new position in shares of Nkarta in the 4th quarter valued at $31,000. Wealth Enhancement Advisory Services LLC purchased a new stake in Nkarta during the first quarter worth $32,000. ProShare Advisors LLC acquired a new stake in Nkarta during the fourth quarter valued at $45,000. Finally, Sei Investments Co. purchased a new position in Nkarta in the fourth quarter valued at $57,000. Institutional investors and hedge funds own 80.54% of the company’s stock.

About Nkarta

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.